2011 xanthigen presentation april 2011

8/17/2019 2011 Xanthigen Presentation April 2011

http://slidepdf.com/reader/full/2011-xanthigen-presentation-april-2011 1/22

THE EFFECTS OF XANTHIGEN IN THE WEIGHT MANAGEMENT OF OBESE

PREMENOPAUSAL WOMEN WITH NON‐ALCOHOLIC FATTY LIVER DISEASE AND

NORMAL LIVER FAT (DIABETES, OBESITY, AND METABOLISM 12:72‐81,2010).

with Polifenoles Naturales



• Obesity and overweight pose a major risk for chronic diseases, including

type 2 diabetes, cardiovascular disease, hypertension and stroke, and

certain forms of cancer, i.e. breast (postmenopausal), endometrium (the

lining of the uterus), colon, kidney, and esophagus. Some studies have

also reported links between obesity and cancers of the gallbladder,

ovar es, an pancreas.

• The non‐fatal, but debilitating health problems associated with obesity

include respiratory difficulties, chronic musculoskeletal problems, skin pro ems an n ert ty.

• In the analyses carried out for World Health Report 2002, approximately

58% of diabetes and 21% of ischemic heart disease and 8‐42% of certain

cancers g o a y were a r u a e o a a ove g m .• The key causes are increased consumption of energy‐dense foods high in

saturated fats and sugars, and reduced physical activity.



The Liver Can Become Fat‐Clogged

Nonalcoholic Fatty

Liver

Disease

(NAFLD)

occurs when fat is not utilized properly

and accumulates inside liver cells. An imbalance in the liver’s ability to regulate

fat roduction distribution and utilization is linked to the radual accumulation

of fat in the body.

Normal Liver (NLF) Fatty Liver (NAFLD)

Less than 5% fat More than 5% fat



Xanthigen

(Undaria pinnatifida and Laminaria japonica) and

Pomegranate Seed Oil (Punica granatum)



Historic Food Use

Brown Seawee

Laminaria (Kombu) and Undaria (Wakame) are the most popularly

consumed brown marine vegetables in soup, salad and snacks.

Wakame and Kombu were originally obtained from wild crops ‐‐ today by

large‐scale cultivation methods in Asia.

Pomegranate

Pomegranate seeds are edible and are often consumed along with the

flesh.

As “anardana” they are used as a spice in Indian, Persian, and Pakistani

cuisine, for example in Aloo Anardana (potatoes with pomegranate seed



TITLE 21‐‐FOOD AND DRUGS

CHAPTER I‐‐FOOD AND DRUG ADMINISTRATION

DEPARTMENT OF HEALTH AND HUMAN SERVICES

SUBCHAPTER E‐‐ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS

• PART 582 ‐‐ SUBSTANCES GENERALLY RECOGNIZED AS SAFE (GRAS)

Subpart A‐‐

General Provisions

Sec. 582.40 Natural extractives (solvent‐free) used in conjunction with spices,

seasonings, and flavorings.

Natural extractives (solvent‐free) used in conjunction with spices, seasonings, and

flavorings that are generally recognized as safe for their intended use, within the

meaning of section 409 of the act, are as follows:

Algae, brown Laminariaspp. andNereocystisspp.



Clinical Study Design

• Institute of Immuno atholo ‐ Russian Academ of Natural Sciences (Moscow)

• Effect of Xanthigen in obese subjects with NLF and NAFLD, double blind placebo controlled, randomized

• ,

• 3 softgels/day (total 600mg Xanthigen/day) ; 1800 kcal prepared diet

• visits 3 times/week and weekly measurements:

Body weight, body fat and liver fat measured by DEXA, resting

energy expenditure measured by indirect calorimetry, waist

circumference, triglycerides, ALT, AST, GGT, CRP, systolic and

Results published: Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of

Xanthigen in the weight management of obese premenopausal women with non-

alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab. 2010

Jan;12(1):72-81.



L D )

Placebo1 Xanthigen1 Placebo2 Xanthigen2

e uce ver a con en prece es o y a oss

n ‐ A l c o h

o l i

L i v e r ( N

A

14

16

18

)

A. Significant NAFLD liver

fat loss at 7 weeks

precedes significant body

N

F a t t y

F )6

8

10

i v e

r F a t (

fat loss at 8 weeks.

H e a l t h

L i v e r ( N

0

2

4

B. Signficant NLF liver fat

loss at 5 weeks precedes

significant body fat loss at 6

weeks.

Time (weeks)

↑ = statistically significant liver fat loss

Diabetes, Obesity,

and

Metabolism

12:72‐81,2010.



Placebo Xanthigen

Effect of Xanthigen on body weight in obese subjects with NLF

94

96

98

)

88

90

92

W e i g h t ( k g s

82

84

86

B o d y First time point showing

statistically significant

weight loss

80

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Time (weeks)

Diabetes, Obesity,

and

Metabolism

12:72‐81,2010.



Placebo Xanthigen

Effect of Xanthigen on body weight in subjects with NAFLD

94

96

)

88

90

92

e i

g h t ( k g

84

86

B o d y

First time point showing

statistically significant

weight loss

80

82

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Diabetes, Obesity,

and

Metabolism

12:72‐81,2010.



Xanthigen vs. Fucoxanthin or Pomegranate Seed Oil

1400

1600

1800

d ) N e t

e **

* p<0.05

800

1000

1200

1670 1686

t o t a l E E / k J

v e r b a s e l i n

*

*±310

±290

200

400

58

591

230

778

1152

159 173

R E E (

±210

±147

±260

±290

±65 ±92±40

±40

Diabetes, Obesity,

and

Metabolism

12:72‐81,2010.



Xanthigen Improves Liver Health Markers

A group of 72 volunteers with fatty liver disease had elevated liver serum

enzymes (ALT, AST and GGT) and C‐reactive protein (a marker of chronic inflammation), which Xanthigen actually improved.

Preclinical and postclinical characteristics of obese non‐diabetic female volunteers with NAFLD and

NLF.

NAFLD NLF

Measurement Pre Placebo Pre XanthPost Placebo Post Xanth Pre Placebo Pre Xanth

Post Placebo Post Xanth

TG, mg/dl 191 ± 15 195 ± 19 180 ± 17 158 ± 21† 174 ± 12 177 ± 12 168 ± 11 155 ± 14§

ALT, U/l 51 ± 9 48 ± 7 40 ± 6 26 ± 7† 31 ± 9‡ 33 ± 7‡ 28 ± 6 26 ± 7§

AST, U/l 53 ± 7 51 ± 5 46 ± 6 29 ± 6† 33 ± 7‡ 38 ± 5‡ 29 ± 6 29 ± 2§

GGT, U/l

49

± 5

47

± 7

46

± 6

31

± 5†

29

± 3‡

27

± 3‡

26

± 2

21

± 3§

CRP, mg/l 6.3 ± 2.1 6.2 ± 2.4 5.4 ± 2.1 3.6 2.2† 5.4 ± 2.4 5.4 ± 2.6 5.1 ± 2.1 3.9 1.8†

†p < 0.05 compared to placebo.

‡p < 0.05 compared to the baseline values in the other cluster.

§ p = NS compared to placebo.

Diabetes, Obesity,

and

Metabolism

12:72‐81,2010.



Summary of Results

• Xanthi en was well tolerated with no safet concerns.

• Xanthigen is effective in reducing body weight and liver fat at a dose of 600mg/day (200mg tid).

• ant gen at t e propose ose n uce a net ncrease o y

KJ/24h which was statistically significant when compared with baseline REE and

with placebo.

• ere was a s a s ca y s gn can re uc on n o y we g a er wee s

and 8 weeks (NAFLD). Participants lost an average of 5.5 kg (NAFLD) and 4.9 kg

(NFL) MORE THAN the placebo groups by the end of the study.



Summary of Results

• The bod wei ht reduction was receded a roximatel 1 week rior b a

significant reduction in the liver fat content on week 5 (NFL) and week 7 (NAFLD).

• The weight reduction correlated with body fat loss and waist circumference

reduction.

• Laboratory parameters (liver enzymes and triglyceride levels) and blood pressure

were also significantly improved compared to baseline.

• an gen seems o possess o er a c v y ene c a o e overa p c ure o

obesity and the related metabolic syndrome



Xanthigen

600mg/day

Proposed Xanthigen Mechanism

Overweight/

ObeseNFL

UCP1 upregulation

Liver Fat

Decrease

Increased Resting

Energy Expenditure

(REE)

Body Weight

Decrease

Improved Levels

of Inflammation

MarkersImproved Blood

Lipids & Liver

Enzymes

Improved

Cardiovascular

Health & Blood

Pressure



Obesity and Liver Health: A unique approach

“The liver

acts

as

a filter

in

the

body

and

once

it

is

‘clogged’

with

fat

it

cannot function properly, a condition clearly linked with fat accumulation

in other tissues and obesity.”

‐‐



Xanthigen ® the “Youth Factor”

Effects of Fucoxanthin, Xanthigen and pomegranate seed oil on SIRT‐1 protein

expression in 3T3‐L1 adipocytes

Fucoxanthin and Xanthigen markedly increased SIRT-1 protein levels in differentiated 3T3-L1 adipocytes,

whereas cells treated with pomegranate seed oil did not show change in SIRT-1 expression as compared to the

untreated, control cells.



Xanthigen ® the “Youth Factor” Future Experimental Directions

Does Xanthigen biological effects share mechanisms of lifespan extension similar to that

afforded with calorie restriction diet? Does Xanthigen has an advantage over the calorie

restriction diet?

1. Insulin production

ancreatic

-cells6. Adiponectin

Table1. The effects of Calorie restrict ion (CR)

on markers of aging


ancreatic



on markers of aging


ancreatic



on markers of aging

2. Fat storage

( white adipose tissue)

3.Insulin sensitivity

7. AMPK activation

( pancreatic -cells)

8. mTOR activation

2. Fat storage



7. AMPK activation


8. mTOR activation

2. Fat storage



7. AMPK activation


8. mTOR activation

(liver and muscles)

4.Glucose and insulin levels

(blood )

5.Glucose uptake

9. Fatty acid oxidation

10. SIRT1

(most tissue)

11. IGF

(liver and muscles)


(blood )

5.Glucose uptake


10. SIRT1

(most tissue)

11. IGF

(liver and muscles)


(blood )

5.Glucose uptake


10. SIRT1

(most tissue)

11. IGF( skeletal muscle and fat pads)

12. ROS

13. Inflammation

(IL-6, TNF-

, NFκ

-B)

( skeletal muscle and fat pads)

12. ROS

13. Inflammation

(IL-6, TNF-

, NFκ

-B)

( skeletal muscle and fat pads)

12. ROS

13. Inflammation

(IL-6, TNF-

, NFκ

-B)



For more information,

please contact PLT at

[email protected]

973‐984‐0900 x 214

www.plthomas.com

Use your smart phone

app to link QR code to

an gen v eo

2011 xanthigen presentation april 2011

Documents